Agios Pharmaceuticals
| Company type | Public |
|---|---|
| Nasdaq: AGIO Russell 1000 Component | |
| Industry | Pharmaceuticals |
| Founded | 2008 |
| Headquarters | , United States |
Key people | Brian Goff (CEO) |
| Revenue | $118 Million(2019) US$ 54.0 million (2025) |
| US$ 412.8 million (2025) | |
| Total assets | US$ 1.30 billion (2025) |
| Total equity | US$ 1.19 billion (2025) |
Number of employees | 536 |
| Website | agios |
| Footnotes / references Foundation | |
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.